Literature DB >> 18781126

Cardiomyopathy in a child with neutropenia and motor delay.

Anthony C McCanta1, Anthony C Chang, Keith Weiner.   

Abstract

A 17-month boy with history of neutropenia and gross motor regression was found to have cardiomyopathy upon admission. He was diagnosed with Barth syndrome: dilated cardiomyopathy, neutropenia, skeletal myopathy, decreased stature, and 3-methylglutaconic aciduria, confirmed by tafazzin gene deletion. This diagnosis should be considered in boys with unexplained neutropenia.

Entities:  

Mesh:

Year:  2008        PMID: 18781126     DOI: 10.1097/MOP.0b013e32830a990a

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  4 in total

Review 1.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

2.  Neutropenia in Barth syndrome: characteristics, risks, and management.

Authors:  Colin G Steward; Sarah J Groves; Carolyn T Taylor; Melissa K Maisenbacher; Birgitta Versluys; Ruth A Newbury-Ecob; Hulya Ozsahin; Michaela K Damin; Valerie M Bowen; Katherine R McCurdy; Michael C Mackey; Audrey A Bolyard; David C Dale
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

Review 3.  Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach.

Authors:  Stacey Reynolds
Journal:  J Multidiscip Healthc       Date:  2015-07-29

4.  Cardiomyopathy in a male patient with neutropenia and growth delay.

Authors:  Veronica Folsi; Nunzia Miglietti; Annamaria Lombardi; Sara Boccacci; Tatiana Utyatnikova; Chiara Donati; Livia Squassabia; Laura Gazzola; Ilaria Bosio; Adele Borghi; Veronica Grassi; Lucia D Notarangelo; Alessandro Plebani
Journal:  Ital J Pediatr       Date:  2014-05-12       Impact factor: 2.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.